Pentosan polysulfate for hip and knee arthritis

Pentosan Polysulfate: A Different Approach to Hip and Knee Arthritis

Dr. David Geier, a sports medicine physician, examines pentosan polysulfate (PPS) as a treatment option for hip and knee arthritis. While most people with osteoarthritis are familiar with cortisone injections and hyaluronic acid (viscosupplementation), PPS is a less commonly discussed option that works through different mechanisms and has an interesting evidence base, particularly from Australia where it has been available as an injectable treatment for over a decade.

Pentosan polysulfate is a semi-synthetic polysaccharide derived from beechwood. It has been used medically for decades in different forms. Oral PPS (brand name Elmiron) is FDA-approved in the United States for interstitial cystitis, a chronic bladder condition. The injectable form, which is the focus of this discussion, targets joint disease specifically and works by addressing the biological processes that drive cartilage breakdown in osteoarthritis.

How PPS Works in the Joint

Osteoarthritis is not simply a wear-and-tear disease where cartilage passively erodes from mechanical use. It is an active biological process involving enzymatic degradation, chronic low-grade inflammation, and changes in the way joint tissues communicate with each other. Understanding this is important because it explains why a compound like PPS, which targets biological pathways, can help even though it does nothing to change the mechanical forces acting on the joint.

PPS works through several mechanisms. First, it inhibits enzymes called matrix metalloproteinases (MMPs) and aggrecanases that actively break down cartilage matrix. In osteoarthritis, these enzymes are upregulated, meaning the joint is dissolving its own cartilage faster than chondrocytes can rebuild it. By slowing this enzymatic destruction, PPS helps shift the balance back toward maintenance and repair.

Second, PPS stimulates the production of proteoglycans and glycosaminoglycans by chondrocytes. These are the molecules that give cartilage its ability to absorb shock and distribute load. When proteoglycan content drops, cartilage becomes stiffer and more vulnerable to mechanical damage. By promoting proteoglycan synthesis, PPS helps restore cartilage's functional properties.

Third, PPS has anti-inflammatory effects within the joint. It reduces the production of inflammatory cytokines and prostaglandins that drive pain and further tissue damage. This anti-inflammatory action provides symptomatic relief while also addressing one of the underlying drivers of disease progression.

Fourth, PPS appears to improve the quality of synovial fluid, which is the lubricant inside the joint. Better synovial fluid means reduced friction, improved nutrient delivery to cartilage, and a healthier overall joint environment.

Clinical Evidence and Patient Outcomes

The evidence base for injectable PPS comes primarily from Australian studies, where the treatment has been used extensively under the brand name Zilosul. Clinical trials have shown that a course of PPS injections can reduce pain, improve joint function, and slow the radiographic progression of osteoarthritis in the knee and hip.

The typical treatment protocol involves a series of subcutaneous or intramuscular injections given weekly for a set period, usually four to six weeks, followed by a maintenance phase. Dr. Geier notes that results are often not immediate. Patients typically start noticing improvement several weeks into the treatment course, which makes sense given that PPS works by modifying the biological environment in the joint rather than providing instant symptom relief like a cortisone injection would.

Studies have shown that the benefits of PPS can persist for months after the treatment course is completed, suggesting that the biological changes it promotes have lasting effects rather than simply wearing off when the drug clears the system. This durability is a significant advantage over cortisone, which provides temporary relief but does not alter the disease process and may actually accelerate cartilage loss with repeated use.

How PPS Compares to Other Joint Treatments

Cortisone injections are the most common injection-based treatment for joint arthritis. They provide rapid pain relief by suppressing inflammation, but the effects typically last only a few weeks to months. Repeated cortisone injections have been associated with accelerated cartilage loss and increased risk of joint replacement in some studies. For this reason, most guidelines recommend limiting cortisone injections to three or four per year in any given joint.

Hyaluronic acid (HA) injections aim to supplement the synovial fluid and improve joint lubrication. The evidence for HA injections is mixed, with some studies showing modest benefit and others showing no significant improvement over placebo. When HA does work, the effects tend to last longer than cortisone (typically three to six months), but the treatment is more expensive and requires multiple injections.

PRP injections use concentrated growth factors from the patient's own blood. The evidence for PRP in osteoarthritis is growing, with several studies showing pain relief and functional improvement, particularly in mild to moderate disease. PRP and PPS work through different but potentially complementary mechanisms, and some practitioners combine them in treatment protocols.

PPS occupies a unique space in this space because it is the only option that directly targets the enzymatic degradation process and stimulates cartilage matrix production. It is disease-modifying rather than purely symptomatic, which gives it a theoretical advantage for long-term outcomes even if the short-term pain relief is less dramatic than a cortisone injection.

Important Safety Considerations

One safety issue that deserves attention is the association between oral pentosan polysulfate (used for bladder conditions) and a rare eye condition called pigmentary maculopathy. Long-term use of oral PPS at the doses used for interstitial cystitis has been linked to changes in the retinal pigment epithelium that can affect vision. This was identified in case reports and observational studies starting around 2018.

The injectable form used for joint disease involves lower total drug exposure than the oral form used for bladder conditions, and the treatment courses are shorter. The risk of maculopathy with injectable PPS at joint-treatment doses appears to be very low based on current data, but patients should be aware of this potential concern and discuss it with their doctor. Regular eye examinations are a reasonable precaution for anyone using PPS, particularly with longer treatment courses.

Other side effects of PPS injections are generally mild and include injection site reactions, mild bleeding or bruising (PPS has mild anticoagulant properties), and occasional gastrointestinal symptoms. The anticoagulant effect means that PPS should be used cautiously in patients on blood-thinning medications, and coagulation parameters should be monitored.

Practical Considerations for Patients

Availability of injectable PPS varies by country and region. In Australia, it is widely available and commonly prescribed for osteoarthritis. In the United States, it is not FDA-approved for joint disease specifically, but it may be accessible through compounding pharmacies or clinical trials. Patients interested in PPS should discuss it with an orthopedic specialist or sports medicine physician who is familiar with the evidence.

PPS is most likely to benefit patients with mild to moderate osteoarthritis who still have some cartilage remaining. For severely arthritic joints with bone-on-bone contact and little remaining cartilage, the disease-modifying effects of PPS have less substrate to work with, and joint replacement may be the more appropriate intervention.

The ideal candidate is someone who wants to delay or potentially avoid joint replacement, who has not responded adequately to conservative measures like exercise, weight management, and physical therapy, and who is looking for an option that goes beyond temporary symptom relief to address the underlying disease process.

The Broader Context of Disease-Modifying Osteoarthritis Treatment

PPS belongs to a category of treatments called disease-modifying osteoarthritis drugs (DMOADs), which aim to change the course of the disease rather than just managing symptoms. This category has been the holy grail of osteoarthritis research for decades, and while no DMOAD has received FDA approval in the United States, PPS is one of the closest compounds to meeting that bar based on the available clinical data.

Other potential DMOADs in development include monoclonal antibodies targeting nerve growth factor (which drives osteoarthritis pain), Wnt pathway modulators (which regulate cartilage and bone metabolism), and cathepsin K inhibitors (which target bone resorption). Each of these targets a different aspect of the osteoarthritis disease process, and the eventual treatment space may involve combining multiple DMOADs to address the disease from several angles simultaneously.

For patients living with osteoarthritis today, PPS represents one of the few available options that goes beyond symptom management to address the underlying disease biology. While access varies by geography and the evidence base is still growing, the mechanistic rationale is strong and the clinical experience from countries where it is widely used supports its effectiveness. Discussing PPS with a sports medicine physician or rheumatologist who stays current with regenerative treatment options is a reasonable step for anyone dealing with progressive joint disease who wants to explore all available options before considering joint replacement surgery.

The cost-benefit calculation for PPS is favorable when compared to the trajectory of untreated osteoarthritis. Joint replacement surgery, while effective, costs tens of thousands of dollars, requires months of rehabilitation, and carries surgical risks including infection, blood clots, and implant failure. If PPS can delay or prevent the need for surgery by slowing disease progression and maintaining joint function, the economic and quality-of-life benefits are substantial. Even a few years of delayed surgery can represent significant value for patients in their fifties and sixties who want to remain active without the limitations and risks of artificial joints.